Enliven Therapeutics, Inc. (ELVN)
Nasdaq: ELVN · Pharmaceutical Preparations · Boulder, CO · filing with the SEC since 2016
Who owns Enliven Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
17
report now, of 34 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 13.3% in Nov 5, 2025
Orbimed Advisors LLC
SCHEDULE 13D/A · filed Jun 24, 2026 · COMMON STOCK · 10.9% in Jun 17, 2026
Polar Capital Holdings Plc
SCHEDULE 13G/A · filed Jun 22, 2026 · Common Stock, $0.001 par value per share · 8.46% in May 15, 2026
Commodore Capital LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · 9.9% in Aug 14, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 5.1% in Jul 17, 2025
Vestal Point Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · 6.5% in Feb 17, 2026
Fairmount Funds Management LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.3% in Aug 14, 2025
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.4% in Nov 14, 2025
What ELVN reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 3, 2026.
Insider tradesForm 4
76sales
0purchases
68sales on a scheduled plan
10people selling
$76.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 54 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Orbimed Advisors LLC | director | 6 | $51.7M | 0 | 0 | $0 |
| Derynck Mika K | director | 1 | $9.6M | 1 | 0 | $0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | 25 | $5.6M | 25 | 0 | $0 |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 10 | $4.5M | 10 | 0 | $0 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | 15 | $1.8M | 14 | 0 | $0 |
| Patel Anish | CHIEF OPERATING OFFICER | 6 | $1.6M | 6 | 0 | $0 |
| Kunkel Lori Anne | director | 5 | $900,000 | 5 | 0 | $0 |
| Garland J. Scott | director | 1 | $600,000 | 0 | 0 | $0 |
| Heyman Richard A. | director | 6 | $400,000 | 6 | 0 | $0 |
| Kintz Samuel | PRESIDENT AND CEO | 1 | $300,000 | 1 | 0 | $0 |